Skip to content

compare the effect of Ketoprofen and Lignocaine skin patches for pain relief in cancer patients

Comparative evaluation of ketoprofen and 5 percentlignocaine transdermal patch as adjuvant to morphine and other pain medications for acute localized area cancer painmanagement - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069061
Enrollment
154
Registered
2024-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C800- Disseminated malignant neoplasm, unspecified Health Condition 2: C509- Malignant neoplasm of breast of unspecified site Health Condition 3: C729- Malignant neoplasm of central nervous system, unspecified Health Condition 4: C759- Malignant neoplasm of endocrine gland, unspecified Health Condition 5: C411- Malignant neoplasm of mandible Health Condition 6: C63- Malignant neoplasm of other and unspecified male genital organs Health Condition 7: C577- Malignant neoplasm of

Interventions

Intervention1: lignocaine patch 5%: application of transdermal lignocaine patch for pain relief in localized cancer patients Patch will be applied twice,each patch for 24 hours over the area of pain.

Sponsors

Norh Eastern Institute of Indira Gandhi Regional Institute of Health and Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult cancer patients who need localized acute localized pain area medication in addition to morphine and other pain medicines. Patients with NRS score of more than 4 .

Exclusion criteria

Exclusion criteria: Patients with known allergy to Local Anaesthetic or NSAID

Design outcomes

Primary

MeasureTime frame
Pain score NRS (0 TO 10) AND VAS(0 TO 100)Timepoint: Post application pain is assessed in 3 HOURS,6 HOURS ,12 HOURS AND 24HOURS,36 HOURS AND 48 HOURS over telephone

Secondary

MeasureTime frame
effect on the quality of life Timepoint: after 48 hours ,then weekly for 1 month

Countries

India

Contacts

Public ContactDr Laltanpuii Sailo

North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences

wendysailo@gmail.com9436154838

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026